SCHEMBL22529620

SCHEMBL22529620

Cc1ccc(C=C2CN(c3ccccc3)CC(=Cc3ccc(C)cc3)C2=O)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.54
▸ MEN1 O00255 4/20 0.54
▸ CYP1A2 P05177 2/20 0.54
▸ ACHE P22303 6/20 0.54
▸ BCHE P06276 2/20 0.52
▸ PTGS2 P35354 2/20 0.51
▸ MAPT P10636 5/20 0.50
▸ ALDH1A1 P00352 4/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ HTT P42858 1/20 0.50
▸ MAPK1 P28482 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ MDM2 Q00987 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ MIF P14174 1/20 0.49
▸ LMNA P02545 2/20 0.47
▸ POLB P06746 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22529619 1.00 KMT2A (0.54) KMT2AMEN1CYP1A2ACHEBCHE
SCHEMBL22550815 1.00 KMT2A (0.54) KMT2AMEN1CYP1A2ACHEBCHE
SCHEMBL22550922 0.89 CYP1A2 (0.60) KMT2AMEN1CYP1A2ACHEBCHE
SCHEMBL22462346 0.84 MAPT (0.66) KMT2ACYP1A2ACHEBCHEPTGS2
SCHEMBL22462347 0.84 MAPT (0.66) KMT2ACYP1A2ACHEBCHEPTGS2
SCHEMBL22822783 0.84 MAPT (0.66) KMT2ACYP1A2ACHEBCHEPTGS2
Diethylamine SCHEMBL8780601 0.81 ALDH1A1 (0.52) KMT2AMEN1CYP1A2ACHEBCHE
SCHEMBL8780598 0.80 CYBB (0.51) KMT2AMEN1ACHEBCHEPTGS2
SCHEMBL22822873 0.80 CASP3 (0.57) KMT2AMEN1BCHEPTGS2MAPT
SCHEMBL22529624 0.80 CASP3 (0.57) KMT2AMEN1BCHEPTGS2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11964943-B2 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof KIAKOS KONSTANTINOS (AT) 2024-04-23 — — US disclosed
US-20200399220-A1 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACTIVITY AND USES THEREOF KIAKOS KONSTANTINOS (AT) 2020-12-24 — — US disclosed
WO-2019097080-A9 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACITIVTY AND USES THEROF KIAKOS KONSTANTINOS (AT) 2020-10-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11964943-B2 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof STAT3, JAK2, STAT6 KMT2A 2566/4885MEN1 3716/4885CYP1A2 4544/4885
US-20200399220-A1 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACTIVITY AND USES THEREOF STAT3, JAK2, STAT6 KMT2A 2566/4885MEN1 3716/4885CYP1A2 4544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback